Systemic chemotherapy's impact on survival and recurrence in people with high-grade glioma has not been conclusively studied.
<h3>What is Systemic chemotherapy?</h3>
Patients undergoing systemic chemotherapy can get their chemotherapy drugs intravenously or orally. The medication may be injected into the body intravenously, or through an IV, or intramuscular, into a muscle (IM).
Some Key features of systemic chemotherapy are-
Background: In order to evaluate the effects of such treatment on survival and recurrence, we conducted a systematic review and meta-analysis.
Methods: From 12 randomised controlled studies, information on 3004 patients was incorporated (11 published and one unpublished).
Findings: Overall, the findings indicated a significant survival extension associated with chemotherapy, with a hazard ratio of 0.85 (95 percent confidence interval [CI] 0.78–0.91, p0.0001) or a relative reduction in mortality risk of 15%. There was no proof that a patient's age, gender, histology, performance status, or degree of resection affected how chemotherapy worked in any particular way.
Interpretation: Further research into pharmacological treatment for malignant tumors is encouraged by this modest but noticeable improvement in survival from chemotherapy.
